BackY-Mabs Therapeutics Overview
Y-Mabs Therapeutics Inc

Y-Mabs Therapeutics Target Price

Y-Mabs Therapeutics target price — quarterly history, peer benchmarks, and growth trends.

Get informed when a big investor buys or sells

+ Follow

Share Price

$8.61

Average Target Price

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2025-08-05Morgan Stanley$8.60.1% downsideOpen
2025-08-05Canaccord Genuity$8.60.1% downsideOpen
2025-08-05Truist Financial$8.60.1% downsideOpen
2025-08-05Cantor Fitzgerald$8.60.1% downsideOpen
2025-08-05Wedbush$8.60.1% downsideOpen
2025-03-05Morgan Stanley$718.7% downsideOpen
2024-11-11BMO CapitalEtzer Darout$24178.7% upsideOpen
2024-06-28Truist FinancialNicole Germino$21143.9% upsideOpen
2024-05-10H.C. WainwrightRobert Burns$22155.5% upsideOpen
2024-04-05BMO CapitalEtzer Darout$26202% upsideOpen
2023-05-10WedbushYMAB)to Outperform$1351% upsideOpen

Y-Mabs Therapeutics (YMAB) FAQ

Stockcircle tracks target price for Y-Mabs Therapeutics (YMAB), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Target Price page is built for Y-Mabs Therapeutics's historical target price trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use target price as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main YMAB overview so you can move from this figure to the surrounding analysis quickly.